Hoshide Reid, Cheung Vincent, Marshall Lawrence, Kasper Ekkehard, Chen Clark C
Division of Neurosurgery, University of California, San Diego, California, USA.
Division of Neurosurgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Surg Neurol Int. 2016 Sep 13;7:84. doi: 10.4103/2152-7806.190439. eCollection 2016.
Neuroprotective strategies for the medical management of traumatic brain injury (TBI) have been elusive. While laboratory studies provide a conceptual framework for the potential efficacy of corticosteroids in this context, clinical trials testing this hypothesis have yielded no convincing evidence of clinical benefit. Here, we review the five key randomized control trials (RCTs) that have examined this issue. Based on the proposed primary endpoints of these RCTs, the five RCTs consistently showed that corticosteroids do not confer significant benefit in the TBI population.
用于创伤性脑损伤(TBI)医学治疗的神经保护策略一直难以捉摸。虽然实验室研究为皮质类固醇在这种情况下的潜在疗效提供了概念框架,但检验这一假设的临床试验并未产生令人信服的临床获益证据。在此,我们回顾五项检验此问题的关键随机对照试验(RCT)。基于这些RCT提出的主要终点,这五项RCT一致表明,皮质类固醇对TBI患者群体并无显著益处。